Stopping propranolol in infantile hemangioma: sudden versus gradual
Part of Cancer clinical trials.
This study compares two ways of stopping propranolol in children with infantile hemangioma (a type of birthmark): stopping suddenly versus slowly reducing the dose. It aims to find out which method is safer and better at preventing the birthmark from growing back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is diagnosed with infantile hemangioma (a type of birthmark made of extra blood vessels).
- Your child has been taking oral propranolol (a medicine to shrink the hemangioma) for at least 6 months.
- The hemangioma has regressed completely or almost completely, with no obvious blood flow seen on ultrasound, and has been stable for 3 months.
- You are willing to complete follow-up visits as scheduled.
- Your child has not had laser, surgery, or steroids for the hemangioma in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at babies with a common birthmark called infantile hemangioma (made of blood vessels) to help doctors decide the best treatment or whether monitoring is enough. It involves a first evaluation and follow-up, but no new drugs or procedures are tested.
This trial tests different starting doses of oral propranolol to see which works best and is safest for treating infantile hemangiomas that have ulcers (sores). It may help your child heal faster.
This trial tests whether giving propranolol by mouth to certain very premature babies with early eye changes can stop retinopathy of prematurity from getting worse. It may help reduce the need for eye treatments later on.
This trial studies whether propranolol, a beta-blocker medicine, can help people with VHL who have non-urgent hemangioblastomas in the brain/spinal cord. It aims to see if the medication is safe and beneficial without needing immediate surgery.
This study compares three approaches—pulsed-dye laser, timolol (a medicated skin solution), or watch-and-wait—to see which works best to slow the growth of a hemangioma birthmark in young babies. It may help find a treatment that shrinks or controls the birthmark as early as possible.
This trial tests a cream containing simvastatin, a cholesterol medicine, applied to infantile hemangiomas (strawberry birthmarks) in babies aged 3-6 months. It may help shrink the birthmark without needing stronger treatments.
Hear when a new Infantile Hemangioma (IH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.